[3] He carried out postdoctoral studies at Harvard University and at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge, England.
[5][6] While an assistant professor of Biochemistry and Molecular Biology at Harvard, and a member of the Cold Spring Harbor Laboratory (CSHL) faculty, Maniatis collaborated with Drs.
[7][8][9][10] This method provided a key step in the isolation of human genes, and in the production of “recombinant” proteins in mammalian cells in culture, a central process in the biotechnology industry.
Maniatis and Ed Fritsch taught a summer course in gene cloning at the Cold Spring Harbor Laboratory.
In 2004 Maniatis cofounded Acceleron Pharma, a TGF-b company that produced “ligand trap” drugs, including REBLOZYL® for the treatment of Myodysplastic Syndrome (MDS) and b-thalassaemia.
[28] Maniatis, David Goeddel, and William Rudder won the Brandeis University Jacob and Louise Gabbay Award in Biotechnology and Medicine in 1999.
[13] Maniatis was a cofounder of the New York Genome Center, headed its scientific steering committee, and has served as a member of its board of directors from its founding in 2011.
[1] Maniatis is founding director of the university-wide Columbia University Precision Medicine Initiative (CPMI), which is dedicated to the application of genomic technology to the advancement of basic and medical science, directed towards the practice of precision medicine (the use of genetic and genomic information to diagnose and treat human diseases).